These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. SCH-530348, a thrombin receptor (PAR-1) antagonist for the prevention and treatment of atherothrombosis. Oestreich J Curr Opin Investig Drugs; 2009 Sep; 10(9):988-96. PubMed ID: 19705342 [TBL] [Abstract][Full Text] [Related]
3. Improving antiplatelet therapy for atherothrombotic disease: preclinical results with SCH 530348, the first oral thrombin receptor antagonist selective for PAR-1. Hildemann SK; Bode C Hamostaseologie; 2009 Nov; 29(4):349-55. PubMed ID: 19882073 [TBL] [Abstract][Full Text] [Related]
4. Oral antiplatelet therapy for atherothrombotic disease: current evidence and new directions. White HD Am Heart J; 2011 Mar; 161(3):450-61. PubMed ID: 21392598 [TBL] [Abstract][Full Text] [Related]
5. The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale. TRA*CER Executive and Steering Committees Am Heart J; 2009 Sep; 158(3):327-334.e4. PubMed ID: 19699853 [TBL] [Abstract][Full Text] [Related]
6. Protease-activated receptor-1 inhibitors: a novel class of antiplatelet agents for the treatment of patients with acute coronary syndrome. Leonardi S; Tricoci P; Becker RC Adv Cardiol; 2012; 47():87-99. PubMed ID: 22906905 [TBL] [Abstract][Full Text] [Related]
7. Mechanism of action and clinical development of platelet thrombin receptor antagonists. Ueno M; Ferreiro JL; Angiolillo DJ Expert Rev Cardiovasc Ther; 2010 Aug; 8(8):1191-200. PubMed ID: 20670195 [TBL] [Abstract][Full Text] [Related]
9. Thrombin receptor antagonism -the potential of antiplatelet medication SCH 530348. Macaulay TE; Allen C; Ziada KM Expert Opin Pharmacother; 2010 Apr; 11(6):1015-22. PubMed ID: 20307225 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial. Morrow DA; Scirica BM; Fox KA; Berman G; Strony J; Veltri E; Bonaca MP; Fish P; McCabe CH; Braunwald E; Am Heart J; 2009 Sep; 158(3):335-341.e3. PubMed ID: 19699854 [TBL] [Abstract][Full Text] [Related]
18. Comparison of the effects of PAR1 antagonists, PAR4 antagonists, and their combinations on thrombin-induced human platelet activation. Wu CC; Teng CM Eur J Pharmacol; 2006 Sep; 546(1-3):142-7. PubMed ID: 16890935 [TBL] [Abstract][Full Text] [Related]
19. Vorapaxar for the reduction of atherothrombotic events. Diaz-Ricart M; Escolar G Drugs Today (Barc); 2014 Nov; 50(11):747-56. PubMed ID: 25525635 [TBL] [Abstract][Full Text] [Related]
20. Review of vorapaxar for the prevention of atherothrombotic events. Wang A Expert Opin Pharmacother; 2015; 16(16):2509-22. PubMed ID: 26480240 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]